摘要
目的 分析双抗血小板治疗轻型卒中对早期神经功能恶化事件的影响及安全性。方法 选择2012年4月-2014年8月入住本院神经内科的轻型卒中患者87例,分为单抗血小板组42例和双抗血小板组45例,单抗血小板组给予阿司匹林肠溶片100 mg,每日1次。双抗血小板组首次给予硫酸氢氯吡格雷负荷剂量300 mg和阿司匹林肠溶片100 mg,第2天起给予氯吡格雷75 mg＋阿司匹林肠溶片100 mg,每日1次。比较两组早期神经功能恶化发生率。结果 单抗血小板组42例中早期神经功能恶化9例（21.43%）,双抗血小板组45例中早期神经功能恶化2例（4.44%）,组间发生率比较差异有统计学意义（P〈0.05）。结论 双抗血小板治疗轻型卒中对预防早期神经功能恶化安全有效。
Objective To analyze the effect and safety of dual antiplatelet therapy for the early neurological deterioration events in patients with mild stroke. Methods A total of 87 cases with light stroke in our hospital department of Neurology from April 2012 to August 2014 admitted to the study,in which 42 cases were as single antiplatelet group,and 45 cases were as dual antiplatelet group. The cases in single antiplatelet group accepted single antiplatelet therapy（Aspirin 100 mg qd）, and the patents in dual antiplatelet group accepted dual antiplatelet therapy（Clopidogrel hydrogen 300 mg and Aspirin 100 mg, clopidogrel hydrogen 75 mg qd and Aspirin 100 mg qd from the second day）. The incidence of early neurological deterioration were measured in the two groups. Results The incidence of early neurological deterioration in dual antiplatelet group[9（21.43）] was lower than single antiplatelet group[2（4.44）], the differences were statistically significant（P〈0.05）. Conclusion Dual antiplatelet therapy for preventing early neurological deterioration in light stroke is safe and effective.
出处
《中国现代医生》
2015年第27期89-91,共3页
China Modern Doctor
基金
浙江省中医药科技研究基金计划(2011ZB168)
浙江省丽水市科技计划项目(2013ZC027)
